Company Description
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States.
Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy.
It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial.
The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.
| Country | United States |
| Founded | 2019 |
| IPO Date | Nov 11, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Louis Garfield Reese IV |
Contact Details
Address: 505 Odyssey Way Exploration Park, Florida 32953 United States | |
| Phone | (254) 244-5739 |
| Website | vaxxinity.com |
Stock Details
| Ticker Symbol | VAXX |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $13.00 |
| CIK Code | 0001851657 |
| CUSIP Number | 92244V104 |
| ISIN Number | US92244V1044 |
| Employer ID | 86-2083865 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Louis Garfield Reese IV | Co-Founder and Executive Chairman of the Board |
| Mei Mei Hu J.D. | Chief Executive Officer and Director |
| Jason Pesile CPA, M.B.A. | Chief Accounting Officer |
| Dr. Jean-Cosme Dodart Ph.D. | Chief Scientific Officer |
| Sumita Ray J.D. | Chief Legal and Administrative Officer |
| Jon Harrison | Chief Government Officer |
| Mark Joinnides MSE | Chief of Staff |
| Amy B. Fix M.B.A., M.S., R.A.C. | Head of Regulatory |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2024 | 15-12G | Securities registration termination |
| May 9, 2024 | DEF 14C | Filing |
| May 2, 2024 | EFFECT | Notice of Effectiveness |
| Apr 30, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 30, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 30, 2024 | POS AM | Post-Effective amendments for registration statement |
| Apr 29, 2024 | 10-K/A | [Amend] Annual report |
| Apr 29, 2024 | PRE 14C | Filing |
| Apr 29, 2024 | 25 | Filing |
| Apr 19, 2024 | 8-K | Current Report |